Brief: Data Presented At Asco Demonstrate Trilaciclib Helps Protect Against Severe Neutropenia, Severe Anemia, And Severe Thrombocytopenia When Given To Extensive-Stage Small Cell Lung Cancer (Es-Sclc) Patients Prior To Chemotherapy

G1 Therapeutics

02/06/2022 16:02

G1 Therapeutics Inc  GTHX.O :
    * DATA PRESENTED AT ASCO DEMONSTRATE TRILACICLIB HELPS
PROTECT
AGAINST SEVERE NEUTROPENIA, SEVERE ANEMIA, AND SEVERE
THROMBOCYTOPENIA WHEN GIVEN TO EXTENSIVE-STAGE SMALL CELL LUNG
CANCER (ES-SCLC) PATIENTS PRIOR TO CHEMOTHERAPY
    * G1 THERAPEUTICS INC - TOTAL NUMBER OF PATIENTS
EXPERIENCING A
MYELOSUPPRESSIVE EVENT WAS LOWER WITH TRILACICLIB COMPARED TO
PLACEBO
    * G1 THERAPEUTICS - PATIENTS RECEIVING TRILACICLIB HAD LOWER
INCIDENCE OF SINGLE-LINEAGE, MULTILINEAGE CHEMOTHERAPY-INDUCED
MYELOSUPPRESSIVE EVENTS

Source text for Eikon:  ID:nGNX5nj1s5 
Further company coverage:  GTHX.O